GTSM:4105

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

TTY Biopharm Company Limited produces and sells various pharmaceuticals and chemical drugs in Taiwan and internationally. More Details


Snowflake Analysis

High growth potential with excellent balance sheet and pays a dividend.


Similar Companies

Share Price & News

How has TTY Biopharm's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4105 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 4105's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

-0.3%

4105

0.6%

TW Pharmaceuticals

-1.0%

TW Market


1 Year Return

-18.5%

4105

40.8%

TW Pharmaceuticals

19.2%

TW Market

Return vs Industry: 4105 underperformed the TW Pharmaceuticals industry which returned 40.8% over the past year.

Return vs Market: 4105 underperformed the TW Market which returned 19.2% over the past year.


Shareholder returns

4105IndustryMarket
7 Day-0.3%0.6%-1.0%
30 Day-8.8%1.6%9.1%
90 Day2.1%-8.1%7.6%
1 Year-14.3%-18.5%43.2%40.8%23.5%19.2%
3 Year-19.1%-30.5%47.9%39.8%43.2%27.3%
5 Year-21.1%-36.8%18.4%8.6%92.9%59.1%

Long-Term Price Volatility Vs. Market

How volatile is TTY Biopharm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TTY Biopharm undervalued compared to its fair value and its price relative to the market?

7.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 4105 (NT$69.5) is trading below our estimate of fair value (NT$75)

Significantly Below Fair Value: 4105 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 4105 is poor value based on its PE Ratio (24.9x) compared to the TW Pharmaceuticals industry average (17.3x).

PE vs Market: 4105 is poor value based on its PE Ratio (24.9x) compared to the TW market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: 4105 is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: 4105 is overvalued based on its PB Ratio (3.3x) compared to the TW Pharmaceuticals industry average (2.3x).


Next Steps

Future Growth

How is TTY Biopharm forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

22.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4105's forecast earnings growth (22.1% per year) is above the savings rate (0.9%).

Earnings vs Market: 4105's earnings (22.1% per year) are forecast to grow faster than the TW market (16.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4105's revenue (13.6% per year) is forecast to grow faster than the TW market (9.1% per year).

High Growth Revenue: 4105's revenue (13.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4105's Return on Equity is forecast to be high in 3 years time (24.7%)


Next Steps

Past Performance

How has TTY Biopharm performed over the past 5 years?

-6.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4105 has high quality earnings.

Growing Profit Margin: 4105's current net profit margins (16.8%) are lower than last year (27.7%).


Past Earnings Growth Analysis

Earnings Trend: 4105's earnings have declined by 6% per year over the past 5 years.

Accelerating Growth: 4105's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4105 had negative earnings growth (-43.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).


Return on Equity

High ROE: 4105's Return on Equity (12.5%) is considered low.


Next Steps

Financial Health

How is TTY Biopharm's financial position?


Financial Position Analysis

Short Term Liabilities: 4105's short term assets (NT$4.8B) exceed its short term liabilities (NT$2.8B).

Long Term Liabilities: 4105's short term assets (NT$4.8B) exceed its long term liabilities (NT$754.9M).


Debt to Equity History and Analysis

Debt Level: 4105's debt to equity ratio (43.2%) is considered high.

Reducing Debt: 4105's debt to equity ratio has reduced from 45.9% to 43.2% over the past 5 years.

Debt Coverage: 4105's debt is well covered by operating cash flow (25.8%).

Interest Coverage: 4105 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is TTY Biopharm current dividend yield, its reliability and sustainability?

5.76%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4105's dividend (5.76%) is higher than the bottom 25% of dividend payers in the TW market (2.11%).

High Dividend: 4105's dividend (5.76%) is in the top 25% of dividend payers in the TW market (5.19%)


Stability and Growth of Payments

Stable Dividend: 4105's dividends per share have been stable in the past 10 years.

Growing Dividend: 4105's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (143.6%), 4105's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 4105's dividends in 3 years are forecast to be covered by earnings (85.4% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

TTY Biopharm has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Kuo-Chiang Chang
Senior VP4.92yrsno datano data
Shu-Wen Wang
Accounting Officer5.25yrsno datano data
Chih-Meng Chang
Vice General Manager of Administration Centerno datano datano data
Jin-Rong Lin
Senior Assist Vice President of Legalno datano datano data
Ru-Fen Chen
Supervisor of Organization Development and Human Resourceno datano datano data
Si-Yuan Yang
Senior Vice President11.5yrsno datano data
Allen Chu
Head of Intensive Care Business Unitno datano datano data

5.3yrs

Average Tenure

Experienced Management: 4105's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tze-Kaing Yang
Director4.42yrsno datano data
Chuan Lin
Chairman2.83yrsno datano data
Ming-Ling Hsueh
Independent Director4.42yrsno datano data
Wen-Hwa Chang
Vice Chairman4.33yrsno datano data
Hsiu-Chi Chang
Director4.42yrsno datano data
Ying-Ying Liao
Director4.42yrsno datano data
Duei Tsai
Independent Director4.42yrsno datano data
Tien-Fu Ling
Independent Director4.42yrsno datano data
Carl Hsiao
Director1.67yrsno datano data

4.4yrs

Average Tenure

Experienced Board: 4105's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TTY Biopharm Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TTY Biopharm Company Limited
  • Ticker: 4105
  • Exchange: GTSM
  • Founded: 1960
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$17.281b
  • Shares outstanding: 248.65m
  • Website: https://eng.tty.com.tw

Location

  • TTY Biopharm Company Limited
  • No.3-1, Park Street
  • 3rd Floor
  • Taipei
  • 11503
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4105GTSM (Taipei Exchange)YesCommon StockTWTWDOct 2001

Biography

TTY Biopharm Company Limited produces and sells various pharmaceuticals and chemical drugs in Taiwan and internationally. It offers oncology drugs, such as Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Ox...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/01 08:33
End of Day Share Price2020/11/30 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.